IMNM

Immunome Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 2/10
  • Value↓ 0/10
Immunome sales and earnings growth
IMNM Growth
Fair
  • Revenue Y/Y↓ -23.23%
  • EPS Y/Y↑ 51.40%
  • FCF Y/Y↓ -70.05%
Immunome gross and profit margin trends
IMNM Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -3060.00%
  • ROIC 5Y↓ -1540.60%
Immunome net debt vs free cash flow
IMNM Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Immunome stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗